HCA Relative Valuation
HCA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCA is overvalued; if below, it's undervalued.
Historical Valuation
HCA Healthcare Inc (HCA) is now in the Fair zone, suggesting that its current forward PE ratio of 14.85 is considered Fairly compared with the five-year average of 13.42. The fair price of HCA Healthcare Inc (HCA) is between 325.35 to 400.41 according to relative valuation methord.
Relative Value
Fair Zone
325.35-400.41
Current Price：376.59
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
-26.75
P/B
Median3y
-34.48
Median5y
-23.20
5.31
FCF Yield
Median3y
6.28
Median5y
8.18
Competitors Valuation Multiple
The average P/S ratio for HCA's competitors is 1.18, providing a benchmark for relative valuation. HCA Healthcare Inc Corp (HCA) exhibits a P/S ratio of 1.23, which is 4.98% above the industry average. Given its robust revenue growth of 5.66%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is HCA Healthcare Inc (HCA) currently overvalued or undervalued?
What is HCA Healthcare Inc (HCA) fair value?
How does HCA's valuation metrics compare to the industry average?
What is the current P/B ratio for HCA Healthcare Inc (HCA) as of May 24 2025?
What is the current FCF Yield for HCA Healthcare Inc (HCA) as of May 24 2025?
What is the current Forward P/E ratio for HCA Healthcare Inc (HCA) as of May 24 2025?